Mengis Capital Management Inc. Trims Stock Position in Bristol-Myers Squibb (NYSE:BMY)

Mengis Capital Management Inc. decreased its position in Bristol-Myers Squibb (NYSE:BMY) by 12.8% in the third quarter, according to its most recent Form 13F filing with the SEC. The firm owned 65,173 shares of the biopharmaceutical company’s stock after selling 9,535 shares during the period. Mengis Capital Management Inc.’s holdings in Bristol-Myers Squibb were worth $3,372,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Haverford Trust Co grew its position in shares of Bristol-Myers Squibb by 0.6% during the 3rd quarter. Haverford Trust Co now owns 67,229 shares of the biopharmaceutical company’s stock worth $3,478,000 after buying an additional 382 shares in the last quarter. Aptus Capital Advisors LLC lifted its stake in Bristol-Myers Squibb by 25.5% in the third quarter. Aptus Capital Advisors LLC now owns 21,738 shares of the biopharmaceutical company’s stock worth $1,125,000 after acquiring an additional 4,421 shares during the period. Commonwealth Retirement Investments LLC grew its holdings in Bristol-Myers Squibb by 8.4% during the 3rd quarter. Commonwealth Retirement Investments LLC now owns 45,487 shares of the biopharmaceutical company’s stock worth $2,354,000 after acquiring an additional 3,541 shares in the last quarter. American Assets Inc. purchased a new position in Bristol-Myers Squibb during the 3rd quarter valued at about $621,000. Finally, Savvy Advisors Inc. purchased a new position in Bristol-Myers Squibb during the 3rd quarter valued at about $250,000. Institutional investors own 76.41% of the company’s stock.

Analyst Ratings Changes

BMY has been the topic of a number of recent research reports. Sanford C. Bernstein began coverage on shares of Bristol-Myers Squibb in a research note on Thursday, October 17th. They set a “market perform” rating and a $56.00 price objective on the stock. Deutsche Bank Aktiengesellschaft dropped their target price on Bristol-Myers Squibb from $53.00 to $45.00 and set a “hold” rating on the stock in a research report on Tuesday, July 23rd. Leerink Partners raised Bristol-Myers Squibb from a “market perform” rating to an “outperform” rating and boosted their price target for the stock from $55.00 to $73.00 in a research report on Tuesday. Cantor Fitzgerald restated a “neutral” rating and set a $50.00 price objective on shares of Bristol-Myers Squibb in a research note on Friday, October 18th. Finally, Morgan Stanley lifted their target price on Bristol-Myers Squibb from $36.00 to $39.00 and gave the company an “underweight” rating in a research note on Tuesday. Two research analysts have rated the stock with a sell rating, thirteen have given a hold rating, one has given a buy rating and two have assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Hold” and an average target price of $54.07.

Insider Activity at Bristol-Myers Squibb

In other Bristol-Myers Squibb news, SVP Phil M. Holzer sold 700 shares of the firm’s stock in a transaction that occurred on Monday, November 4th. The shares were sold at an average price of $55.62, for a total transaction of $38,934.00. Following the completion of the transaction, the senior vice president now directly owns 11,760 shares of the company’s stock, valued at approximately $654,091.20. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. In related news, EVP Samit Hirawat bought 1,830 shares of the stock in a transaction dated Friday, November 1st. The shares were purchased at an average price of $54.67 per share, for a total transaction of $100,046.10. Following the completion of the purchase, the executive vice president now directly owns 62,109 shares of the company’s stock, valued at $3,395,499.03. This represents a 0.00 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, SVP Phil M. Holzer sold 700 shares of the firm’s stock in a transaction dated Monday, November 4th. The stock was sold at an average price of $55.62, for a total value of $38,934.00. Following the sale, the senior vice president now directly owns 11,760 shares in the company, valued at approximately $654,091.20. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 0.09% of the stock is owned by insiders.

Bristol-Myers Squibb Stock Down 1.3 %

NYSE:BMY opened at $59.02 on Wednesday. The company has a current ratio of 1.24, a quick ratio of 1.09 and a debt-to-equity ratio of 2.83. Bristol-Myers Squibb has a twelve month low of $39.35 and a twelve month high of $61.08. The company has a market cap of $119.70 billion, a PE ratio of -16.44, a P/E/G ratio of 21.63 and a beta of 0.44. The company’s 50 day moving average is $52.24 and its two-hundred day moving average is $46.99.

Bristol-Myers Squibb (NYSE:BMY) last announced its quarterly earnings data on Thursday, October 31st. The biopharmaceutical company reported $1.80 earnings per share for the quarter, beating analysts’ consensus estimates of $1.49 by $0.31. Bristol-Myers Squibb had a negative net margin of 15.30% and a positive return on equity of 11.94%. The firm had revenue of $11.89 billion for the quarter, compared to analyst estimates of $11.26 billion. During the same period in the previous year, the company earned $2.00 earnings per share. The business’s quarterly revenue was up 8.4% compared to the same quarter last year. Analysts anticipate that Bristol-Myers Squibb will post 0.92 EPS for the current year.

Bristol-Myers Squibb Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Friday, November 1st. Investors of record on Friday, October 4th were issued a dividend of $0.60 per share. This represents a $2.40 dividend on an annualized basis and a dividend yield of 4.07%. The ex-dividend date of this dividend was Friday, October 4th. Bristol-Myers Squibb’s dividend payout ratio (DPR) is -66.85%.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.